Oraqix (Lidocaine, Prilocaine)

Lidocaine, the active ingredient in Oraqix, is a local anesthetic presented as a dental topical formulation for intra‑oral use. It provides surface anesthesia for dental procedures and oral mucosal treatments. Oraqix also contains prilocaine, which works synergistically to enhance the anesthetic effect.

GNH USA supplies Oraqix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oraqix is a topical dental anesthetic used to numb the oral mucosa during various procedures.

- Dental extractions: provides rapid surface anesthesia to facilitate painless tooth removal. - Periodontal surgery: enables comfortable probing, flap elevation, and minor surgical interventions. - Oral mucosal lesions: reduces discomfort during treatment of ulcers, biopsies, or other lesions.

Oraqix may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Transient burning or stinging sensation at the application site. - Mild swelling or erythema of the mucosa. - Temporary alteration of taste perception. - Minor irritation or discomfort lasting a few minutes.

Serious or Rare Side Effects: - Allergic reactions, including anaphylaxis. - Methemoglobinemia, particularly associated with prilocaine. - Systemic toxicity presenting as CNS symptoms (e.g., seizures) or cardiovascular depression. - Severe tissue necrosis if applied excessively. - Persistent numbness beyond the expected duration. - Hypotension or arrhythmias in susceptible individuals.

Before using Oraqix, clinicians should consider several safety measures.

- Allergy assessment: verify no hypersensitivity to amide‑type local anesthetics. - Medical history: avoid in patients with severe cardiac conduction disorders. - Concurrent medications: exercise caution when other local anesthetics are used. - Dosage limit: adhere to recommended maximum volume for the treatment area. - Pregnancy and lactation: use only if the benefit outweighs potential risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Oraqix can interact with other drugs, necessitating careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may increase plasma levels of lidocaine. - CYP2D6 inhibitors (e.g., fluoxetine): can elevate prilocaine metabolites leading to methemoglobinemia. - Other local anesthetics: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask early signs of systemic toxicity. - Diuretics: can alter plasma concentration of the anesthetics. - General anesthetics: potential synergistic CNS depression during combined procedures.